Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Both his parents died from cancer during his first two years at Cambridge. His father was 60 and his mother was 58. As an undergraduate Sanger's beliefs were strongly influenced by his Quaker upbringing. He was a pacifist and a member of the Peace Pledge Union. It was through his involvement with the Cambridge Scientists' Anti-War Group that he met his future wife, Joan Howe, who was studying economics at Newnham College. They courted while he was studying for his Part II exams and married after he had graduated in December 1940. Sanger, although brought up and influenced by his religious upbringing, later began to lose sight of his Quaker related ways. He began to see the world through a more scientific lens, and with the growth of his research and scientific development he slowly drifted farther from the faith he grew up with. He had nothing but respect for the religious and states he took two things from it, truth and respect for all life. Under the Military Training Act 1939 he was provisionally registered as a conscientious objector, and again under the National Service (Armed Forces) Act 1939, before being granted unconditional exemption from military service by a tribunal. In the meantime he undertook training in social relief work at the Quaker centre, Spicelands, Devon and served briefly as a hospital orderly. Sanger began studying for a PhD in October 1940 under N.W. "Bill" Pirie. His project was to investigate whether edible protein could be obtained from grass. After little more than a month Pirie left the department and Albert Neuberger became his adviser.
== Medical applications – intravenous access and fluid delivery == The Hagen–Poiseuille equation is useful in determining the vascular resistance and hence flow rate of intravenous (IV) fluids that may be achieved using various sizes of peripheral and central cannulas. The equation states that flow rate is proportional to the radius to the fourth power, meaning that a small increase in the internal diameter of the cannula yields a significant increase in flow rate of IV fluids. The radius of IV cannulas is typically measured in "gauge", which is inversely proportional to the radius. Peripheral IV cannulas are typically available as (from large to small) 14G, 16G, 18G, 20G, 22G, 26G. As an example, assuming cannula lengths are equal, the flow of a 14G cannula is 1.73 times that of a 16G cannula, and 4.16 times that of a 20G cannula. It also states that flow is inversely proportional to length, meaning that longer lines have lower flow rates. This is important to remember as in an emergency, many clinicians favor shorter, larger catheters compared to longer, narrower catheters. While of less clinical importance, an increased change in pressure (∆p) — such as by pressurizing the bag of fluid, squeezing the bag, or hanging the bag higher (relative to the level of the cannula) — can be used to speed up flow rate. It is also useful to understand that viscous fluids will flow slower (e.g. in blood transfusion). Delivery of fluids such as antibiotics or analgesics by means of an elastomeric pump can also be understood in terms of a Poiseuille-flow model.
==== Difficulties with interpretation of TSH measurement ==== Heterophile antibodies (which include human anti-mouse antibodies (HAMA) and Rheumatoid Factor (RF)), which bind weakly to the test assay's animal antibodies, causing a higher (or less commonly lower) TSH result than the actual true TSH level. Although the standard lab assay panels are designed to remove moderate levels of heterophilic antibodies, these fail to remove higher antibody levels. "Dr. Baumann [from Mayo Clinic] and her colleagues found that 4.4 percent of the hundreds of samples she tested were affected by heterophile antibodies.........The hallmark of this condition is a discrepancy between TSH value and free T4 value, and most important between laboratory values and patient's conditions. Endocrinologists, in particular, should be on alert for this." Macro-TSH - endogenous antibodies bind to TSH reducing its activity, so the pituitary gland would need to produce more TSH to obtain the same overall level of TSH activity. TSH Isomers - natural variations of the TSH molecule, which have lower activity, so the pituitary gland would need to produce more TSH to obtain the same overall level of TSH activity. The same TSH concentration may have a different meaning whether it is used for diagnosis of thyroid dysfunction or for monitoring of substitution therapy with levothyroxine. Reasons for this lack of generalisation are Simpson's paradox and the fact that the TSH-T3 shunt is disrupted in treated hypothyroidism, so that the shape of the relation between free T4 and TSH concentration is distorted.
In contrast to his father, Carl saw his mother as unreliable and inconsistent, which caused him to associate women more broadly as having an "innate unreliability" (Later, these early impressions were revised: "I have trusted men friends and been disappointed by them, and I have mistrusted women and was not disappointed."). Emilie was an eccentric and depressed woman; she spent considerable time in her bedroom, where she said spirits visited her at night. Though she was normal during the day, Jung recalled that at night, his mother became strange and mysterious. He said that one night, he saw a faintly luminous and indefinite figure coming from her room, with a head detached from the neck and floating in the air in front of the body. Jung had a better relationship with his father.
=== Effectiveness evaluation === A 2013 article published in The Lancet reported that the MenAfriVac vaccination campaign in Chad reduced meningitis incidence by 94%. In three regions of Chad, approximately 1.8 million people from 1 to 29 years old received a single dose of the vaccine in December 2011. Vaccinating 70% of the population in that age group is enough to create "herd immunity". During the 2012 meningitis season no cases of the meningococcus sub-type serogroup A caused disease in places where mass vaccination took place. Carriers of serogroup A were found to decrease by more than 97% post-vaccination. Surveillance is needed to continue for several more years to establish the length of effective period of the vaccine and whether other meningococci serogroups may surge to replace serogroup A. In November 2015, a special collection of 29 articles was published in the journal Clinical Infectious Diseases—with guest editors from Public Health England and the former Meningitis Vaccine Project about the steps taken for the development, introduction, and evaluation of MenAfriVac. Immunization with MenAfriVac has led to the control and near elimination of deadly meningitis A disease in the African "meningitis belt". In 2013, only four laboratory-confirmed cases of meningitis A were reported by the 26 countries in the meningitis belt. But scientists warned that unless countries within the belt incorporate the meningitis A vaccine in routine immunization schedules for infants, there is a risk that the disease could rebound in 15 years' time.
Sources: en.wikipedia.org
Sutherland goes further to say that deviancy is contingent on conflicting groups within society, and that such groups struggle over the means to define what is criminal or deviant within society. Criminal organizations therefore gravitate around illegal avenues of production, profit-making, protectionism or social control and attempt (by increasing their operations or membership) to make these acceptable. This also explains the propensity of criminal organizations to develop protection rackets, to coerce through the use of violence, aggression and threatening behavior (at times termed 'terrorism'). Preoccupation with methods of accumulating profit highlight the lack of legitimate means to achieve economic or social advantage, as does the organization of white-collar crime or political corruption (though it is debatable whether these are based on wealth, power or both). The ability to effect social norms and practices through political and economic influence (and the enforcement or normalization of criminogenic needs) may be defined by differential association theory.
==== De Novo synthesis ==== The de novo biosynthesis of arginine in humans begins with glutamine. This compound is deaminated to glutamic acid and subsequently converted to glutamate-5-semialdehyde. Transamination of a second glutamic acid molecule produces ornithine, which enters the urea cycle.
(The capital Greek letter "Δ" (delta) corresponds to Roman "D", for Double bond). Thus, for example, the 20-carbon arachidonic acid is Δ5,8,11,14, meaning that it has double bonds between carbons 5 and 6, 8 and 9, 11 and 12, and 14 and 15. In the context of human diet and fat metabolism, unsaturated fatty acids are often classified by the position of the double bond closest between to the ω carbon (only), even in the case of multiple double bonds such as the essential fatty acids. Thus linoleic acid (18 carbons, Δ9,12), γ-linolenic acid (18-carbon, Δ6,9,12), and arachidonic acid (20-carbon, Δ5,8,11,14) are all classified as "ω−6" fatty acids; meaning that their formula ends with –CH=CH–CH2–CH2–CH2–CH2–CH3. Fatty acids with an odd number of carbon atoms are called odd-chain fatty acids, whereas the rest are even-chain fatty acids. The difference is relevant to gluconeogenesis.
Related to its ability to dissolve many salts, DMSO is a common ligand in coordination chemistry. Illustrative is the complex dichlorotetrakis(dimethyl sulfoxide)ruthenium(II) (RuCl2(dmso)4). In this complex, three DMSO ligands are bonded to ruthenium through sulfur. The fourth DMSO is bonded through oxygen. In general, the oxygen-bonded mode is more common. In carbon tetrachloride solutions DMSO functions as a Lewis base with a variety of Lewis acids such as I2, phenols, trimethyltin chloride, metalloporphyrins, and the dimer Rh2Cl2(CO)4. The donor properties are discussed in the ECW model. The relative donor strength of DMSO toward a series of acids, versus other Lewis bases, can be illustrated by C-B plots.
=== EC 2.3.2: Aminoacyltransferases === EC 2.3.2.1: D-glutamyltransferase EC 2.3.2.2: γ-glutamyltransferase EC 2.3.2.3: lysyltransferase EC 2.3.2.4: Now classified as EC 4.3.2.9, γ-glutamylcyclotransferase EC 2.3.2.5: glutaminyl-peptide cyclotransferase EC 2.3.2.6: leucyltransferase EC 2.3.2.7: aspartyltransferase EC 2.3.2.8: arginyltransferase EC 2.3.2.9: agaritine γ-glutamyltransferase EC 2.3.2.10: UDP-N-acetylmuramoylpentapeptide-lysine N6-alanyltransferase EC 2.3.2.11: alanylphosphatidylglycerol synthase EC 2.3.2.12: peptidyltransferase EC 2.3.2.13: protein-glutamine g-glutamyltransferase EC 2.3.2.14: D-alanine γ-glutamyltransferase EC 2.3.2.15: glutathione γ-glutamylcysteinyltransferase EC 2.3.2.16: lipid II:glycine glycyltransferase EC 2.3.2.17: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-glycyl)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.18: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-triglycine)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.19: ribostamycin:4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoyl-[BtrI acyl-carrier protein] 4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoate transferase EC 2.3.2.20: cyclo(L-leucyl-L-phenylalanyl) synthase EC 2.3.2.21: cyclo(L-tyrosyl-L-tyrosyl) synthase EC 2.3.2.22: cyclo(L-leucyl-L-leucyl) synthase EC 2.3.2.23: E2 ubiquitin-conjugating enzyme EC 2.3.2.24: (E3-independent) E2 ubiquitin-conjugating enzyme EC 2.3.2.25: N-terminal E2 ubiquitin-conjugating enzyme EC 2.3.2.26: HECT-type E3 ubiquitin transferase EC 2.3.2.27: RING-type E3 ubiquitin transferase EC 2.3.2.28: L-allo-isoleucyltransferase EC 2.3.2.29: aspartate/glutamate leucyltransferase EC 2.3.2.30: L-ornithine Nα-acyltransferase EC 2.3.2.31: RBR-type E3 ubiquitin transferase EC 2.3.2.32: cullin-RING-type E3 NEDD8 transferase EC 2.3.2.33: RCR-type E3 ubiquitin transferase EC 2.3.2.34: E2 NEDD8-conjugating enzyme EC 2.3.2.35: capsaicin synthase EC 2.3.2.36: RING-type E3 ubiquitin transferase (cysteine targeting)
Sources: en.wikipedia.org
=== Center for Chemical Genomics === A high-throughput screening (HTS) facility is a central component of the Center for Chemical Genomics (CCG). This core facility is designed to assist academic researchers in carrying out high-throughput screens of chemical libraries and to identify new tools for biological research.
== Louisiana Secretary of Revenue (1996–1999) == Following his first stint in state government, Kennedy returned to private law practice until 1996. That year, he was appointed secretary of the state Department of Revenue in the cabinet of Governor Mike Foster. Despite having political differences with Kennedy during his time in Roemer's administration, Foster selected Kennedy for the position and later endorsed him for the U.S. Senate. Kennedy stepped down as secretary in April 1999 and was replaced by Brett Crawford.
A precarious number of people managed to return to responsible work, while at the other extreme, people were left with severe and disabling impairments. Most people fell into an intermediate group, left with some improvement of their symptoms but also with emotional and intellectual deficits to which they made a better or worse adjustment. On average, there was a mortality rate of approximately 5% during the 1940s. A survey of British lobotomy patients lobotomised between 1942 and 1954 found that 13% of patients were deemed to have made a full recovery and a further 28% were deemed to have made a significant recovery; for 25% lobotomy was deemed to have made no change and 4% died as a result of the surgery. Patients after lobotomy can have a lowering and stabilising of blood pressure. They may have inertia, struggle to complete test problems, and might suffer from metabolic disorders. They may also be considered dispassionate about their feelings because they lack a strong emotional component. It is reported that the patients face less anxiety and stress, but have a constant feel of depression. The frontal lobotomy procedure could have severe negative effects on a patient's personality and ability to function independently. Lobotomy patients often show a marked reduction in initiative and inhibition. They may also exhibit difficulty imagining themselves in the position of others because of decreased cognition and detachment from society. Walter Freeman coined the term "surgically induced childhood" and used it constantly to refer to the results of lobotomy.
Surgery to remove the prostate is called prostatectomy, and is usually done as a treatment for cancer limited to the prostate, or for prostatic enlargement. When it is done, it may be done as open surgery or as laparoscopic (keyhole) surgery. These are done under general anaesthetic. Usually the procedure for cancer is a radical prostatectomy, which means that the seminal vesicles are removed and the vasa deferentia are also tied off. Part of the prostate can also be removed from within the urethra, called transurethral resection of the prostate (TURP). Open surgery may involve a cut that is made in the perineum, or via an approach that involves a cut down the midline from the belly button to the pubic bone. Open surgery may be preferred if there is a suspicion that lymph nodes are involved and they need to be removed or biopsied during a procedure. A perineal approach will not involve lymph node removal and may result in less pain and a faster recovery following an operation. A TURP procedure uses a tube inserted into the urethra via the penis and some form of heat, electricity or laser to remove prostate tissue. The whole prostate can be removed. Complications that might develop because of surgery include urinary incontinence and erectile dysfunction because of damage to nerves during the operation, particularly if a cancer is very close to nerves. Ejaculation of semen will not occur during orgasm if the vasa deferentia are tied off and seminal vesicles removed, such as during a radical prosatectomy. This will mean a man becomes infertile.
=== Whey-protein beverages === Whey-protein beverages were central to these technological developments that began in 1969, and Malaspina played a seminal role in their early commercialization. His approach to the Dairy Board concerned soluble whey protein specifically for carbonated acidic beverages, and he continued to press for sufficient quantities for market testing as Coca-Cola and the New Zealand industry developed beverage-grade whey protein concentrate. Coca-Cola also installed an ultrafiltration pilot plant in Brazil specifically to produce whey protein concentrate. That development program led to Tai, a whey-fortified, orange-flavored carbonated beverage launched by Coca-Cola in Brazil in 1971. Malaspina's nutritional beverage program subsequently led to Sansón, a pasteurized whey-protein beverage marketed by Coca-Cola in Mexico. These early products anticipated the much broader use of whey protein in nutritional beverages. By the late 1980s, whey proteins were gaining commercial importance in sports nutrition, weight management, and medical nutrition, with sports and nutritional beverages becoming significant applications for whey protein concentrate and, later, for whey protein isolate. Improvements in membrane filtration, diafiltration, and protein fractionation now enable manufacturers to produce whey ingredients with higher protein concentrations, improved solubility, and other properties tailored to different beverage formulations.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.